Arterial Patency in Liver Transplantation

NCT03275883 | Completed

• 1 other identifier: 2016-01889
• Study Type: observational
• Target: 567
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to determine the risk profile of hepatic artery occlusion in liver transplant recipients who received an aortohepatic conduits, analyzing all consecutive cadaveric liver transplantations from July 2007 to 31st December 2016. Medical records will be examined and adverse events will be analyzed and categorized using the Clavien-Dindo classification and Comprehensive Complication Index.

Conditions

Aortohepatic Conduit; Patency Rate; Liver Transplantation

Outcome Measures

Primary Outcomes (3)

• Independent risk factors

  To identify independent risk factors for early and late occlusion of arterial conduits in liver transplantation.

  June 2007 til 31st December 2016

• Placement sites

  To compare different placement sites (infrarenal, supraceliac, iliacal, etc.) of arterial conduits in terms of occlusion rates and graft survival

  June 2007 til 31st December 2016

• Patency Rates

  To investigate whether antiplatelet therapy is protective in terms of arterial patency.

  June 2007 til 31st December 2016

Interventions

Aortohepatic Conduit PROCEDURE

Placement of an interposition graft between hepatic artery and aorta during liver transplantation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who recieved an aorto-hepatic conduit during liver transplantation

You may qualify if:

• Liver transplantation requiring aorto-hepatic or iliac-hepatic conduits
• Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)
• Whole organ as well as split allografts
• Primary liver transplantation as well as liver retransplantation
• Recipient age ≥18 years

You may not qualify if:

• Living donor liver transplantation
• Pediatric liver transplantation (recipient age \<18 years)
• Arterial reconstruction other than aorto-hepatic or iliac-hepatic conduits
• Multivisceral transplantations

Sponsors & Collaborators

• University of Zurich: lead
• University Hospital Birmingham NHS Foundation Trust: collaborator
• Medical University Innsbruck: collaborator
• University of Bologna: collaborator
• The Leeds Teaching Hospitals NHS Trust: collaborator
• University of California, Los Angeles: collaborator
• Johannes Gutenberg University Mainz: collaborator
• Rennes University Hospital: collaborator
• University of Lyon: collaborator
• University of Rochester: collaborator
• University of Southern California: collaborator

Study Sites (1)

University Hospital Zurich

Zurich, 8091, Switzerland

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 5, 2017
• First Posted: September 8, 2017
• Study Start: September 1, 2017
• Primary Completion: September 5, 2018
• Study Completion: December 1, 2019
• Last Updated: March 18, 2020

Record last verified: 2020-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP

Locations

CH (1)